Compare MLCI & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MLCI | IXHL |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | Australia |
| Employees | 21 | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 37.0M |
| IPO Year | N/A | 2024 |
| Metric | MLCI | IXHL |
|---|---|---|
| Price | $2.78 | $3.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.0K | ★ 263.6K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.68 | $0.16 |
| 52 Week High | $8.68 | $6.39 |
| Indicator | MLCI | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 48.30 |
| Support Level | $2.68 | $2.68 |
| Resistance Level | $3.13 | $3.68 |
| Average True Range (ATR) | 0.18 | 0.36 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 15.90 | 54.48 |
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The company's reporting segments include asset management and insurance. The company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The Asset Management segment comprises all fee generating activities. The Insurance Solutions segment, which derives maximum revenue, consists of two product lines within the insurance business, LTC and MYGA.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.